BRCA2 and breast cancer: To examine the potential effect of the 21 prioritized BRCA1 and BRCA2 5′ noncoding variants on regulatory activity, promoter activity was measured using luciferase assays in MCF7 and MDA‐MB‐468 BC cell lines.